Liminatus Pharma, Inc.LIMN
Price (close)
$4.18
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$12.5M
Dividend yield
—
1-year total return
-94.2%
Net margin
—
Revenue growth
—
Debt / equity
4.80x
What Liminatus Pharma, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net income | — | -$3.5M | -$10.2M |
| Free cash flow | — | — | -$10.0M |
More on LIMN.
- Liminatus Pharma, Inc. summary
- Liminatus Pharma, Inc. financial statements
- Liminatus Pharma, Inc. key metrics
- Liminatus Pharma, Inc. health scores and style box
- Liminatus Pharma, Inc. earnings
- Liminatus Pharma, Inc. dividends
- Liminatus Pharma, Inc. valuation
- Liminatus Pharma, Inc. ownership and insiders
- Liminatus Pharma, Inc. peers
Figures from Liminatus Pharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.